March 29, 2023
Mochida Pharmaceutical and Human Life CORD Japan said on March 28 that they have sealed a joint commercialization pact in Japan for the regenerative medicine product HLC-001, targeting intractable diseases including non-infectious pulmonary complications (NIPCs) after hematopoietic stem cell transplantation...read more